Publication

Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice: A possible role for adiponectin and miR-21?

Morrison, M. C., Yakala, G. K., Liang, W., Wielinga, P. Y., Salic, K., van Koppen, A., Tomar, T., Kleemann, R., Heeringa, P. & Kooistra, T. Jun-2017 In : Scientific Reports. 7, 10 p., 2915

Research output: Scientific - peer-reviewArticle

APA

Morrison, M. C., Yakala, G. K., Liang, W., Wielinga, P. Y., Salic, K., van Koppen, A., ... Kooistra, T. (2017). Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice: A possible role for adiponectin and miR-21? Scientific Reports, 7, [2915]. DOI: 10.1038/s41598-017-02444-2

Author

Morrison, Martine C. ; Yakala, Gopala K. ; Liang, Wen ; Wielinga, Peter Y. ; Salic, Kanita ; van Koppen, Arianne ; Tomar, Tushar ; Kleemann, Robert ; Heeringa, Peter ; Kooistra, Teake. / Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice : A possible role for adiponectin and miR-21?. In: Scientific Reports. 2017 ; Vol. 7.

Harvard

Morrison, MC, Yakala, GK, Liang, W, Wielinga, PY, Salic, K, van Koppen, A, Tomar, T, Kleemann, R, Heeringa, P & Kooistra, T 2017, 'Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice: A possible role for adiponectin and miR-21?' Scientific Reports, vol 7, 2915. DOI: 10.1038/s41598-017-02444-2

Standard

Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice : A possible role for adiponectin and miR-21? / Morrison, Martine C.; Yakala, Gopala K.; Liang, Wen; Wielinga, Peter Y.; Salic, Kanita; van Koppen, Arianne; Tomar, Tushar; Kleemann, Robert; Heeringa, Peter; Kooistra, Teake.

In: Scientific Reports, Vol. 7, 2915, 06.2017.

Research output: Scientific - peer-reviewArticle

Vancouver

Morrison MC, Yakala GK, Liang W, Wielinga PY, Salic K, van Koppen A et al. Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice: A possible role for adiponectin and miR-21? Scientific Reports. 2017 Jun;7. 2915. Available from, DOI: 10.1038/s41598-017-02444-2


BibTeX

@article{d176f1e65b3741d2b6a54410502828c3,
title = "Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice: A possible role for adiponectin and miR-21?",
abstract = "Obesity-related albuminuria is associated with decline of kidney function and is considered a first sign of diabetic nephropathy. Suggested factors linking obesity to kidney dysfunction include low-grade inflammation, insulin resistance and adipokine dysregulation. Here, we investigated the effects of two pharmacological compounds with established anti-inflammatory properties, rosiglitazone and rosuvastatin, on kidney dysfunction during high-fat diet (HFD)-induced obesity. For this, human CRP transgenic mice were fed standard chow, a lard-based HFD, HFD+ rosuvastatin or HFD+ rosiglitazone for 42 weeks to study effects on insulin resistance; plasma inflammatory markers and adipokines; and renal pathology. Rosiglitazone but not rosuvastatin prevented HFD-induced albuminuria and renal fibrosis and inflammation. Also, rosiglitazone prevented HFD-induced KIM-1 expression, while levels were doubled with rosuvastatin. This was mirrored by miR-21 expression, which plays a role in fibrosis and is associated with renal dysfunction. Plasma insulin did not correlate with albuminuria. Only rosiglitazone increased circulating adiponectin concentrations. In all, HFD-induced albuminuria, and renal inflammation, injury and fibrosis is prevented by rosiglitazone but not by rosuvastatin. These beneficial effects of rosiglitazone are linked to lowered miR-21 expression but not connected with the selectively enhanced plasma adiponectin levels observed in rosiglitazone-treated animals.",
keywords = "PROXIMAL TUBULAR CELLS, C-REACTIVE PROTEIN, DIABETES-MELLITUS, ALBUMINURIA, OBESITY, DISEASE, INFLAMMATION, DYSFUNCTION, RECEPTOR, INSULIN",
author = "Morrison, {Martine C.} and Yakala, {Gopala K.} and Wen Liang and Wielinga, {Peter Y.} and Kanita Salic and {van Koppen}, Arianne and Tushar Tomar and Robert Kleemann and Peter Heeringa and Teake Kooistra",
year = "2017",
month = "6",
doi = "10.1038/s41598-017-02444-2",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

RIS

TY - JOUR

T1 - Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice

T2 - Scientific Reports

AU - Morrison,Martine C.

AU - Yakala,Gopala K.

AU - Liang,Wen

AU - Wielinga,Peter Y.

AU - Salic,Kanita

AU - van Koppen,Arianne

AU - Tomar,Tushar

AU - Kleemann,Robert

AU - Heeringa,Peter

AU - Kooistra,Teake

PY - 2017/6

Y1 - 2017/6

N2 - Obesity-related albuminuria is associated with decline of kidney function and is considered a first sign of diabetic nephropathy. Suggested factors linking obesity to kidney dysfunction include low-grade inflammation, insulin resistance and adipokine dysregulation. Here, we investigated the effects of two pharmacological compounds with established anti-inflammatory properties, rosiglitazone and rosuvastatin, on kidney dysfunction during high-fat diet (HFD)-induced obesity. For this, human CRP transgenic mice were fed standard chow, a lard-based HFD, HFD+ rosuvastatin or HFD+ rosiglitazone for 42 weeks to study effects on insulin resistance; plasma inflammatory markers and adipokines; and renal pathology. Rosiglitazone but not rosuvastatin prevented HFD-induced albuminuria and renal fibrosis and inflammation. Also, rosiglitazone prevented HFD-induced KIM-1 expression, while levels were doubled with rosuvastatin. This was mirrored by miR-21 expression, which plays a role in fibrosis and is associated with renal dysfunction. Plasma insulin did not correlate with albuminuria. Only rosiglitazone increased circulating adiponectin concentrations. In all, HFD-induced albuminuria, and renal inflammation, injury and fibrosis is prevented by rosiglitazone but not by rosuvastatin. These beneficial effects of rosiglitazone are linked to lowered miR-21 expression but not connected with the selectively enhanced plasma adiponectin levels observed in rosiglitazone-treated animals.

AB - Obesity-related albuminuria is associated with decline of kidney function and is considered a first sign of diabetic nephropathy. Suggested factors linking obesity to kidney dysfunction include low-grade inflammation, insulin resistance and adipokine dysregulation. Here, we investigated the effects of two pharmacological compounds with established anti-inflammatory properties, rosiglitazone and rosuvastatin, on kidney dysfunction during high-fat diet (HFD)-induced obesity. For this, human CRP transgenic mice were fed standard chow, a lard-based HFD, HFD+ rosuvastatin or HFD+ rosiglitazone for 42 weeks to study effects on insulin resistance; plasma inflammatory markers and adipokines; and renal pathology. Rosiglitazone but not rosuvastatin prevented HFD-induced albuminuria and renal fibrosis and inflammation. Also, rosiglitazone prevented HFD-induced KIM-1 expression, while levels were doubled with rosuvastatin. This was mirrored by miR-21 expression, which plays a role in fibrosis and is associated with renal dysfunction. Plasma insulin did not correlate with albuminuria. Only rosiglitazone increased circulating adiponectin concentrations. In all, HFD-induced albuminuria, and renal inflammation, injury and fibrosis is prevented by rosiglitazone but not by rosuvastatin. These beneficial effects of rosiglitazone are linked to lowered miR-21 expression but not connected with the selectively enhanced plasma adiponectin levels observed in rosiglitazone-treated animals.

KW - PROXIMAL TUBULAR CELLS

KW - C-REACTIVE PROTEIN

KW - DIABETES-MELLITUS

KW - ALBUMINURIA

KW - OBESITY

KW - DISEASE

KW - INFLAMMATION

KW - DYSFUNCTION

KW - RECEPTOR

KW - INSULIN

U2 - 10.1038/s41598-017-02444-2

DO - 10.1038/s41598-017-02444-2

M3 - Article

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 2915

ER -

ID: 42711424